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Abstract
Background: CD26, dipeptidyl peptidase IV, was discovered firstly as a membrane-associated peptidase on the surface of
leukocyte. We previously demonstrated that a subpopulation of CD26+ cells were associated with the development of
distant metastasis, enhanced invasiveness and chemoresistance in colorectal cancer (CRC). In order to understand the
clinical impact of CD26, the expression was investigated in CRC patient’s specimens. This study investigated the prognostic
significance of tumour CD26 expression in patients with CRC. Examination of CD26+ cells has significant clinical impact for
the prediction of distant metastasis development in colorectal cancer, and could be used as a selection criterion for further
therapy.
Methods: Tumour CD26 expression levels were studied by immunohistochemistry using Formalin-fixed paraffin embedded
(FFPE) tissues in 143 patients with CRC. Tumour CD26 expression levels were correlated with clinicopathological features of
the CRC patients. The prognostic significance of tumour tissue CD26 expression levels was assessed by univariate and
multivariate analyses.
Result: CD26 expression levels in CRC patients with distant metastasis were significantly higher than those in non-
metastatic. High expression levels of CD26 were significantly associated with advanced tumour staging. Patients with a high
CD26 expression level had significantly worse overall survival than those with a lower level (p,0.001).
Conclusions: The expression of CD26 was positively associated with clinicopathological correlation such as TNM staging,
degree of differentiation and development of metastasis. A high CD26 expression level is a predictor of poor outcome after
resection of CRC. CD26 may be a useful prognostic marker in patients with CRC.
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Introduction
Colorectal cancer (CRC) is the third most common malignancy
and leading cause of cancer death in the world [1]. Approximately
50% of patients with CRC develop liver metastases, cancer
patients with metastasis have higher mortality than just primary
tumour alone [2,3]. Liver is the most common site of distant
metastasis in CRC patients with poor prognosis. Therefore,
understanding the biological mechanism of metastasis is important
for prognosis of metastasis in CRC.
CD26 – also known as dipeptidyl peptidase IV, is a 110-kDa cell
surface glycoprotein protein with multiple functions, and is widely
expressed in most cell types including T lymphocytes, endothelial
and epithelial cells. It is a type II membrane-bound protein and
member of prolyl peptidase family with carboxy terminus facing
extracellular space. It is also composed of a transmembrane region
and a short cytoplasmic domain. CD26 acts as other prolyl
peptidase family: its carboxy terminal extracellular domain
regulates the activities of a number of cytokines and chemokines
through removal of the N-terminal dipeptide from polypeptides
with proline or alanine in the penultimate position [4,5]. CD26
can hydrolyse amino acid on matrix metalloproteinase [6]. CD26
was demonstrated as a binding partner with fibronectin and
collagen in a variety of experimental conditions [7,8,9]. CD26
interacts with type I and III collagens and fibronectin, which
proteolysis the ECM and result in facilitating the tumour cells
migration, invasion and metastasis [10,11,12,13]. Based on its
ability to regulate biological molecules through its enzymatic
activity, CD26 can act as a tumour suppressor or activator.
Our lab previously demonstrated that a subpopulation of
CD26+ cells were associated with the development of distant
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metastasis in colorectal cancer through binding to extracellular
matrix components such as fibronectin and collagen, and
regulating the expression of EMT markers [13]. Besides its
expression on tumour cell surface, the truncated form (sCD26/
DPPIV) is also present in body fluids such as serum, and its levels
are correlated with tumour status and behaviour for certain
cancers. Serum CD26 levels were suggested as an early diagnosis
and predictive marker of colorectal cancer [14]. Higher levels of
circulating CD26 have been identified in CRC patients with
metastatic disease [15]. All of these studies suggested that CD26 is
a potential biomarker for CRC diagnosis and prognosis. The
patient’s specimens are another way to be used for detecting CD26
expression level by immunohistochemistry. Therefore, the aim of
the present study was to clarify the prognostic significance of
CD26 expression in patients with colorectal cancer.
Patients and Methods
One hundred and forty three patients (81 men and 62 women;
median age 73, range 29–92 years) who underwent resection of
CRC at Queen Mary Hospital, The University of Hong Kong,
between August 2008 and November 2011 were studied. No
patient had received any preoperative treatment. The specimens
were fixed with formalin and embedded with paraffin wax. The
study was approved by Institutional Review Board of the
University of Hong Kong/Hospital Authority Hong Kong West
Cluster (HKU/HA HKW IRB), and the written informed consent
was obtained from the patients for participation.
To evaluate the prognostic significance of CD26 expression in
CRC patients, the association between CD26 expression and
survival was studied. Five micrometres tissue sections were cut and
antigen retrieval was achieved by boiling the sections in citric
buffer, pH 8.0, in an oven for 10 mins. Adjacent normal colorectal
tissues were used as controls, and negative controls were
performed by replacing the CD26 antibody (Novus Biologicals,
LLC) with phosphate buffered saline. Positive signals were
evaluated by two independent assessors who were unaware of
clinical outcomes, in five fields under light microscopy at a
magnification of 400X. Staining intensity was scored as follows: 0-
negative staining; 1-weak staining; 2-moderate staining and 3-
strong staining.
All clinicopathological data and follow-up results were collected
prospectively in a computerized database. Tumours were staged
according to the pathological tumour node metastasis (TNM)
classification. All patients were monitored every 3 months for
detection of any recurrence or distant metastasis. The last patient
in the cohort had been followed for 21 months.
Figure 1. Immunostaining for CD26 on normal colon and CRC patient’s specimen. (A-D) Colorectal cancer patient specimen with strong,
moderate, weak and negative CD26 staining, respectively. (E) Normal colon. Magnification with 200x and 400x.
doi:10.1371/journal.pone.0098582.g001
Prognostic Significance of CD26 on CRC Patients
PLOS ONE | www.plosone.org 2 May 2014 | Volume 9 | Issue 5 | e98582
Statistical analysis
The x2 test (or Fisher exact test where appropriate) was used for
nominal variables. Survival rates were calculated by the Kaplan
Meier method and compared between groups by the log rank test.
Multivariate analysis of prognostic factors was performed by the
Cox proportional hazard model. All statistical analyses were
performed by SPSS 16 for Windows statistical software (SPSS,
Chicago, IL). P value,0.05 was considered statistically significant.
Results
CD26 was expressed in CRC tumour specimens with different
expression levels which were classified into four groups according
to their staining intensity (strong, moderate, weak and negative
staining) (Fig. 1). The CD26 expression level was further classified
into high (staining intensity 2, 3) and low (staining intensity 0, 1)
expression. The possible association between CD26 expression
level and clinicopathological data was also examined (Table 1).
There was no significant relationship observed between CD26
expression level and age, gender or tumour size. However,
significantly higher CD26 expression was correlated with poorly
differentiated tumour, late TNM stage, and presence of metastasis
(especially liver metastasis). Moreover, CD26 expression was
significantly associated with TNM stage III and stage IV (Table 2).
The median follow-up duration of the 143 patients with CRC
was 32 months (range 0–60). The 1-, 3- and 5-year overall survival
rates were 91, 66 and 66 per cent respectively in patients with high
CD26 expression, and 96, 94 and 78 per cent respectively in those
with low CD26 levels (P,0.001) (Fig. 2A). The survival curve of
CRC patients included in this study is plotted in Figure 2B. The
median disease-free survival time was 33 months (range 0–60) and
the percentages of tumour recurrence were 25.2% and 5.1% for
patients with high and low CD26 expression in five years,
respectively. It means that the disease-free survival of patients with
Table 1. CD26 expression categorized by clinicopathological data of CRC patients.
Variable No. of casesa CD26 Expression
a
P*
Low(n=98) High(n=45)
Age (years old): .65 42 24 18 0.075
#65 101 74 27
Gender: Male 81 56 25 0.858
Female 62 42 20
Tumour size (cm3): .5 51 35 16 1.000
#5 92 63 29
Degree of Differentiation: Well and moderate 132 94 38 0.029
Poor 7 2 5
TNM stage: Stage I/II 66 57 9 ,0.001
Stage III/IV 76 40 36
Metastasis statusb: No metastasis 116 92 24 ,0.001
Metastasis 27 6 21
Liver Metastasis: No 123 92 31 ,0.001
Yes 20 6 14
TNM, tumour node metastasis.
aThe total number of cases may be less than 143 because of missing information.
bPatients with distant metastasis were classified as ‘‘Metastasis’’.
*x2 test (or Fisher exact test in 2-sided)
doi:10.1371/journal.pone.0098582.t001
Table 2. CD26 expression categorized by TNM stage of CRC patients.
Variable No. of casesa Percentage CD26 Expression
a
P*
Low High
TNM stage (I, II and III, n = 115):
Stage I/II 66 57% 57 9 0.037
Stage III 49 43% 34 15
TNM stage (I, II and IV, n = 93):
Stage I/II 66 71% 57 9 ,0.001
Stage IV 27 29% 6 21
TNM, tumour node metastasis.
aThe total number of cases may be less than 143 because of missing information.
*x2 test (or Fisher exact test in 2-sided)
doi:10.1371/journal.pone.0098582.t002
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high CD26 expression was significantly worse than that of patients
with low CD26 level (P=0.001). Results shown in Figure 3 suggest
that there was significant differences between patients with
metastasis and those without metastasis in either overall survival
(P,0.001) or disease-free survival (P,0.001). The percentages of
tumour recurrence were 44.4% and 3.4% for patients with distant
metastasis and without distant metastasis in five years, respectively.
Besides CD26 expression, table 3 shows the results of a
univariate analysis of patient’s clinicopathological features which
might affect prognosis. From these parameters, only TNM stage,
Figure 2. High CD26 expression associated with worse overall and disease free survival of colorectal cancer patients. A) Kaplan-Meier
cumulative overall survival curves of CRC patients with high (expression level 3 and 2) and low CD26 expression. P,0.001 (log rank test). B) Kaplan-
Meier disease free survival for CRC patients stratified by high and low CD26 expression. P = 0.001 (log rank test).
doi:10.1371/journal.pone.0098582.g002
Prognostic Significance of CD26 on CRC Patients
PLOS ONE | www.plosone.org 4 May 2014 | Volume 9 | Issue 5 | e98582
metastatic status and liver metastasis had significant long-term
outcome in this study.
When CD26 expression (high versus low levels) was entered into
a Cox regression analysis together with these three factors, only
metastatic status was identified as independent prognostic factors
of overall survival (Table 4A). However, CD26 expression level
was an independent prognostic factor of overall survival when
CD26 expression was entered into a Cox regression analysis
together without metastatic status (Table 4B).
Figure 3. Metastasis associated with worse overall and disease free survival of colorectal cancer patients. A) Kaplan-Meier cumulative
overall survival curves of CRC patients with metastasis and no metastasis. P,0.001 (log rank test). B) Kaplan-Meier disease free survival for CRC
patients stratified by metastasis and no metastasis. P,0.001 (log rank test).
doi:10.1371/journal.pone.0098582.g003
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To study the response of chemotherapy, CRC patients with
different CD26 expression were analysed with or without
chemotherapy (5-Fu or oxaliplatin) (Fig. 4). The result showed
that high CD26 expression was associated with worse overall
survival whether with or without chemotherapy (P = 0.013 and
0.012 respectively). On the other hand, there was no significant
effect of chemotherapy on CRC patients with high or low CD26
expression (Fig. 5). Figure 5A suggest that CRC patients with high
CD26 expression seems have better survival for the first year with
chemotherapy, but the survival became worse afterwards.
Discussion
Colorectal cancer (CRC) is one of the most leading cause of
cancer deaths in the world due to asymptomatic early stage and
mostly diagnosis in advanced stages [1]. The 5 year survival rate of
CRC patients with metastatic disease is less than 10% [16].
Colonoscopy and faecal occult blood test (FOBT) in stool are the
two most common screening tool for CRC [17,18,19]. However,
they have different disadvantages and limitations such as high cost
for the population with low risk, discomfort of patients or low
sensitivity [20]. Besides an asymptomatic early stage, metastasis is
the major cause of high mortality in CRC. In order to predict the
outcome of colorectal cancer accurately, there has been great
interest to develop factors which can help for diagnosis or
prognosis because survival can be dramatically improved at early
detection and treatment of CRC [21].
CD26 is a multifunctional cell surface glycoprotein protein with
intrinsic dipeptidyl peptidase IV (DPPIV) activity which widely
expressed in most cell types. Cell surface proteases participate in
cancer progression and malignant transformation by facilitating
tumour cell invasion and metastasis [22]. Yamada K et al. recently
demonstrated that anti-CD26 monoclonal antibody induced
nuclear localization of CD26 from cell surface which can inhibit
tumour cell growth [23]. Several studies have indicated that serum
CD26 can be an early diagnostic marker for colorectal cancer
[15,24,25]. However, they did not clarify whether CD26
expression had any independent prognostic significance. More-
over, the reports were conflicted in the concentration of soluble
CD26 in CRC patients: one study found out that soluble CD26
was significantly higher in healthy donors, but another report
showed higher level of soluble CD26 was detected in CRC
patients. It varies among different papers, which may due to
different detection methods in the study (one used ELISA assay
and another one used an assay for enzyme activity).
Our previous study has clearly demonstrated that a subpopu-
lation of cancer cells with CD26 expression were associated with
the metastatic progression and chemoresistance of colorectal
cancer [13]. Based on our previous findings, we further
investigated the potential prognostic properties of CD26 expres-
sion on CRC patient’s specimens.
In this study, our results showed that the high CD26 expression
level was a significant predictor of both reduced overall survival
(P,0.001, log rank test) and disease free survival (P=0.001) in
Table 3. Significant prognostic factors of overall survival by univariate analysis.
Variable No. of cases 5-year survival (%) P*
TNM stage:
Stage I/II 64 92.4 0.021
Stage III/IV 78 77.6
Metastasis status:
No metastasis 116 93.1 ,0.001
Metastasis 27 44.4
Liver metastasis:
No 123 90.2 ,0.001
Yes 30 45
*Log rank test
doi:10.1371/journal.pone.0098582.t003
Table 4. Prognostic factors of overall survival by Cox regression analysis.
A: Variable Hazard ratio P*
TNM stage (I/II versus III/IV) 0.466 (0.089, 2.44) 0.366
CD26 expression (Low versus High) 1.953 (0.674, 5.656) 0.218
Metastasis status (No Metastasis versus Metastasis) 10.556 (1.731, 64.367) 0.011
Liver Metastasis (No versus Yes) 1.279 (0.392, 4.176) 0.683
B: Variable Hazard ratio P*
TNM stage (I/II versus III/IV) 1.029 (0.301, 3.514) 0.964
CD26 expression (Low versus High) 2.967 (1.122, 7.83) 0.028
Liver Metastasis (No versus Yes) 4.897 (1.772, 13.536) 0.002
Values in parentheses are 95% confidence intervals.
*Log rank test
doi:10.1371/journal.pone.0098582.t004
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patients with CRC under univariate analysis, which means that
higher CD26 expression has worse survival rate and higher rate of
recurrence. Even though there is no correlation between CD26
expression and age, gender or tumour size, a significant difference
in degree of differentiation (P=0.029, chi-square test), TNM stage
(P,0.001) or metastatic status (P,0.001) show that CD26
expression was positively associated with tumour differentiation,
invasion and metastasis. It indicated that higher CD26 expression
had poorer differentiation and higher potential for developing
distant metastasis. Moreover, CD26 also has significant higher
Figure 4. High CD26 expression associated with worse overall survival of colorectal cancer patients with or without chemotherapy.
Kaplan-Meier cumulative overall survival curves of CRC patients with (A) and without (B) chemotherapy. P = 0.013 and 0.012 respectively (log rank
test).
doi:10.1371/journal.pone.0098582.g004
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expression on TNM stage III (P=0.037) or stage IV (P,0.001),
which demonstrated that high expression of CD26 was associated
with late TNM stage. In multivariate analysis, CD26 expression is
a long-term survival independent pathological variable which have
clinical implications when comparing with tumour stage
(P=0.028). It indicated that CD26 expression was a more
significant prognostic marker than TNM stage. However, in the
multivariate analysis including metastatic status, CD26 expression
was not an independent predictor of overall survival which may
due to dominant effect of metastatic status on patient survival.
CD26 has a function of binding to extracellular matrix proteins
which may have a role in tumour migration and metastasis.
Figure 5. Chemotherapy has no effect on overall survival of colorectal cancer patients with high or low CD26 expression. Kaplan-
Meier cumulative overall survival curves of CRC patients with high (A) or low (B) CD26 expression. P = 0.514 and 0.661 respectively (log rank test).
doi:10.1371/journal.pone.0098582.g005
Prognostic Significance of CD26 on CRC Patients
PLOS ONE | www.plosone.org 8 May 2014 | Volume 9 | Issue 5 | e98582
Recent studies have demonstrated that CD26 binds to fibronectin
and type 1 collagen, which are major components of the
extracellular matrix, to facilitate the metastatic progression and
invasive phenotype in CRC through down-regulation of
E-cadherin [26,27,28]. Additionally, CD26+ cells were shown to
possess greater cancer stem cell properties and chemoresistance
when compared with CD26- cells [13]. Our previous findings also
suggest that the CD26 protein in CD26+ cells does not only
provide them with adhesion to both fibronectin and type I
collagen but also give them EMT-like attributes, which contributes
to the invasive phenotype and metastatic capacity of the CD26+
cells. It is consistent with our findings that CD26 expression is
significantly associated with metastatic status (P,0.001). Taken
together, it provides a potential explanation as to why higher
CD26 expression is associated with poorer survival in CRC
patients.
The new metastases is still frequently developed even the
tumour response has been improved for systemic chemotherapy
on CRC. There are more than 80% in situ tumour recurrences for
CRC patients even after apparently complete radiological
response to chemotherapy for liver metastasis [29]. As demon-
strated in our previous in vitro and in vivo studies, CD26+ cancer
stem cell subpopulation had enhanced chemoresistance [13].
Therefore, CRC patients with high CD26 expression may fail to
eradicate the CD26+ cells under chemotherapeutic treatments
which led to enrichment of CD26+ cells and ultimately cause
further metastasis and worse survival after first year of treatment.
Chemotherapy (5-Fu and oxaliplatin) didn’t show improvement on
CRC patients survival after surgical resection, it is crucial for
development new therapeutic strategies targeting such CD26+
cancer stem cell.
Carcinoembrynoic antigen (CEA) is a tumour-associated
antigen which was identified in CRC tissue in 1965 [30]. Patient’s
sera CEA level, who have tumours of digestive tract, was used as a
most common diagnostic and prognostic marker for CRC
[31,32,33,34]. However, the postoperative CEA values were
stabilized after 12th post-operative week and the mean time of
detectable rise in CEA for CRC patients is more than 3 months
[35], which may lose the most suitable time for adjuvant therapy.
On the contrary, the CD26 expression level can be detected after
operation and the result can be used for prognosis.
In conclusion, our findings suggest that the specimen CD26
expression level is an independent prognostic marker which
predicts survival significantly before development of metastasis,
and it can provide additional prognostic information and allow
selection of CRC patients at high risk of tumour recurrence or
development metastasis for adjuvant or neoadjuvant therapy.
CD26 expression may be a useful prognostic marker in patients
with CRC after surgical resection.
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